Update on alcoholic hepatitis

Biomolecules

Volumn 5, Issue 4, 2015, Pages 2978-2986

  Torok, Natalie J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Northern California Health Care System   (United States)

Author keywords

Alcoholic liver injury; IL22; Oxidative stress; Steatohepatitis; TNF

Indexed keywords

ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 2; BILIRUBIN; CORTICOSTEROID; CREATININE; CYTOCHROME P450 2E1; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 22; INTERLEUKIN 6; PENTOXIFYLLINE; PREDNISOLONE; PROCALCITONIN; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADAPTIVE IMMUNITY; AGE; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; CLINICAL FEATURE; DISCRIMINANT ANALYSIS; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; HUMAN; INNATE IMMUNITY; INSULIN RESISTANCE; INTESTINE FLORA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICAL HISTORY; MODEL FOR END STAGE LIVER DISEASE SCORE; MULTICENTER STUDY (TOPIC); NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STELLATE CELL; STEM CELL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TH1 CELL; ANIMAL; HEPATITIS, ALCOHOLIC;

ANIMALS; HEPATITIS, ALCOHOLIC; HUMANS;

EID: 85012078081     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom5042978     Document Type: Review

References (54)

1. Zakhari, S.; Li, T.K. Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease. Hepatology 2007, 46, 2032-2039.
2. Rehm, J.; Mathers, C.; Popova, S.; Thavorncharoensap, M.; Teerawattananon, Y.; Patra, J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009, 373, 2223-2233.
3. White, A.M.; Hingson, R.W.; Pan, I.J.; Yi, H.Y. Hospitalizations for alcohol and drug overdoses in young adults ages 18-24 in the United States, 1999-2008: Results from the nationwide inpatient sample. J. Stud. Alcohol. Drugs 2011, 72, 774-786.
4. Alexander, J.F.; Lischner, M.W.; Galambos, J.T. Natural history of alcoholic hepatitis. II. The long-term prognosis. Am. J. Gastroenterol. 1971, 56, 515-525.
5. Poynard, T.; Mathurin, P.; Lai, C.L.; Guyader, D.; Poupon, R.; Tainturier, M.H.; Myers, R.P.; Muntenau, M.; Ratziu, V.; Manns, M.; et al. A comparison of fibrosis progression in chronic liver diseases. J. Hepatol. 2003, 38, 257-265.
6. Mathurin, P.; Beuzin, F.; Louvet, A.; Carrié-Ganne, N.; Balian, A.; Trinchet, J.C.; Dalsoglio, D.; Prevot, S.; Naveau, S. Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. Aliment. Pharmacol. Ther. 2007, 25, 1047-1054.
7. Stickel, F.; Buch, S.; Lau, K.; Meyer zu Schwabedissen, H.; Berg, T.; Ridinger, M.; Rietschel, M.; Schafmayer, C.; Braun, F.; Hinrichsen, H.; et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 2011, 53, 86-95.
8. Tian, C.; Stokowski, R.P.; Kershenobich, D.; Ballinger, D.G.; Hinds, D.A. Variant in PNPLA3 is associated with alcoholic liver disease. Nat. Genet. 2010, 42, 21-23.
9. Salameh, H.; Raff, E.; Erwin, A.; Seth, D.; Nischalke, H.D.; Falleti, E.; Burza, M.A.; Leathert, J.; Romeo, S.; Molinaro, A.; et al. PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. Am. J. Gastroenterol. 2015, doi:10.1038/ajg.2015.137.
10. Salameh, H.; Raff, E.; Erwin, A.; Seth, D.; Nischalke, H.D.; Falleti, E.; Burza, M.A.; Leathert, J.; Romeo, S.; Molinaro, A.; et al. Corrigendum: PNPLA3 Gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. Am. J. Gastroenterol. 2015, doi:10.1038/ajg.2015.181.
11. Tsukamoto, H. Metabolic reprogramming and cell fate regulation in alcoholic liver disease. Pancreatology 2015, 15, S61-S65.
12. Lucey, M.R.; Mathurin, P.; Morgan, T.R. Alcoholic hepatitis. N. Engl. J. Med. 2009, 360, 2758-2769.
13. Savolainen, V.T.; Liesto, K.; Mannikko, A.; Penttila, A.; Karhunen, P.J. Alcohol consumption and alcoholic liver disease: Evidence of a threshold level of effects of ethanol. Alcohol. Clin. Exp. Res. 1993, 17, 1112-1117.
14. Casanova, J.; Bataller, R. Alcoholic hepatitis: Prognosis and treatment. Gastroenterol. Hepatol. 2014, 37, 262-268.
15. Altamirano, J.; Miquel, R.; Katoonizadeh, A.; Abraldes, J.G.; Duarte-Rojo, A.; Louvet, A.; Augustin, S.; Mookerjee, R.P.; Michelena, J.; Smyrk, T.C.; et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 2014, 146, 1231-1239.
16. Dunn, W.; Angulo, P.; Sanderson, S.; Jamil, L.H.; Stadheim, L.; Rosen, C.; Malinchoc, M.; Kamath, P.S.; Shah, V.H. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 2006, 131, 1057-1063.
17. Naveau, S.; Giraud, V.; Borotto, E.; Aubert, A.; Capron, F.; Chaput, J.C. Excess weight risk factor for alcoholic liver disease. Hepatology 1997, 25, 108-111.
18. Carithers, R.L., Jr.; Herlong, H.F.; Diehl, A.M.; Shaw, E.W.; Combes, B.; Fallon, H.J.; Maddrey, W.C. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann. Intern. Med. 1989, 110, 685-690.
19. Dunn, W.; Jamil, L.H.; Brown, L.S.; Wiesner, R.H.; Kim, W.R.; Menon, K.V.; Malinchoc, M.; Kamath, P.S.; Shah, V. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005, 41, 353-358.
20. Dominguez, M.; Rincón, D.; Abraldes, J.G.; Miquel, R.; Colmenero, J.; Bellot, P.; García-Pagán, J.C.; Fernández, R.; Moreno, M.; Bañares, R.; et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am. J. Gastroenterol. 2008, 103, 2747-2756.
21. Louvet, A.; Naveau, S.; Abdelnour, M.; Ramond, M.J.; Diaz, E.; Fartoux, L.; Dharancy, S.; Texier, F.; Hollebecque, A.; Serfaty, L.; et al. The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007, 45, 1348-1354.
22. Mathurin, P.; Lucey, M.R. Management of alcoholic hepatitis. J. Hepatol. 2012, 56, S39-S45.
23. Michelena, J.; Altamirano, J.; Abraldes, J.G.; Affò, S.; Morales-Ibanez, O.; Sancho-Bru, P.; Dominguez, M.; García-Pagán, J.C.; Fernández, J.; Arroyo, V.; et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology 2015, 62, 762-772.
24. Mathews, S.; Xu, M.; Wang, H.; Bertola, A.; Gao, B. Animals models of gastrointestinal and liver diseases. Animal models of alcohol-induced liver disease: Pathophysiology, translational relevance, and challenges. Am. J. Physiol. Gastrointest. Liver Physiol. 2014, 306, G819-G823.
25. Bertola, A.; Park, O.; Gao, B. Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: A critical role for E-selectin. Hepatology 2013, 58, 1814-1823.
26. Thiele, G.M.; Klassen, L.W.; Tuma, D.J. Formation and immunological properties of aldehyde-derived protein adducts following alcohol consumption. Methods Mol. Biol. 2008, 447, 235-257.
27. Viitala, K.; Makkonen, K.; Israel, Y.; Lehtimäki, T.; Jaakkola, O.; Koivula, T.; Blake, J.E.; Niemelä, O. Autoimmune responses against oxidant stress and acetaldehyde-derived epitopes in human alcohol consumers. Alcohol. Clin. Exp. Res. 2000, 24, 1103-1109.
28. Tuma, D.J.; Casey, C.A. Dangerous byproducts of alcohol breakdown—Focus on adducts. Alcohol. Res. Health 2003, 27, 285-290.
29. Ceni, E.; Mello, T.; Galli, A. Pathogenesis of alcoholic liver disease: Role of oxidative metabolism. World J. Gastroenterol. 2014, 20, 17756-17772.
30. Cederbaum, A.I. Cytochrome P450 2E1-dependent oxidant stress and upregulation of anti-oxidant defense in liver cells. J. Gastroenterol. Hepatol. 2006, 21, S22-S25.
31. Thakur, V.; McMullen, M.R.; Pritchard, M.T.; Nagy, L.E. Regulation of macrophage activation in alcoholic liver disease. J. Gastroenterol. Hepatol. 2007, 22, S53-S56.
32. Fernandez-Checa, J.C.; Hirano, T.; Tsukamoto, H.; Kaplowitz, N. Mitochondrial glutathione depletion in alcoholic liver disease. Alcohol 1993, 10, 469-475.
33. Lu, Y.; Zhuge, J.; Wang, X.; Bai, J.; Cederbaum, A.I. Cytochrome P450 2E1 contributes to ethanol-induced fatty liver in mice. Hepatology 2008, 47, 1483-1494.
34. Nguyen-Khac, E.; Thevenot, T.; Piquet, M.A.; Benferhat, S.; Goria, O.; Chatelain, D.; Tramier, B.; Dewaele, F.; Ghrib, S.; Rudler, M.; et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N. Engl. J. Med. 2011, 365, 1781-1789.
35. Yan, A.W.; Fouts, D.E.; Brandl, J.; Stärkel, P.; Torralba, M.; Schott, E.; Tsukamoto, H.; Nelson, K.E.; Brenner, D.A.; Schnabl, B. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011, 53, 96-105.
36. Chen, P.; Starkel, P.; Turner, J.R.; Ho, S.B.; Schnabl, B. Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology 2015, 61, 883-894.
37. Enomoto, N.; Ikejima, K.; Yamashina, S.; Hirose, M.; Shimizu, H.; Kitamura, T.; Takei, Y.; Sato And, N.; Thurman, R.G. Kupffer cell sensitization by alcohol involves increased permeability to gut-derived endotoxin. Alcohol. Clin. Exp. Res. 2001, 25, 51S-54S.
38. Yin, M.; Bradford, B.U.; Wheeler, M.D.; Uesugi, T.; Froh, M.; Goyert, S.M.; Thurman, R.G. Reduced early alcohol-induced liver injury in CD14-deficient mice. J. Immunol. 2001, 166, 4737-4742.
39. Blackmore, L.J.; Ryan, J.M.; Huang, X.; Hussain, M.; Triantafyllou, E.; Vergis, N.; Vijay, G.M.; Antoniades, C.G.; Thursz, M.R.; Jassem, W.; et al. Acute alcoholic hepatitis and cellular Th1 immune responses to alcohol dehydrogenase. Lancet 2015, doi:10.1016/S0140-6736(15)60337-3.
40. Markwick, L.J.; Riva, A.; Ryan, J.M.; Cooksley, H.; Palma, E.; Tranah, T.H.; Manakkat Vijay, G.K.; Vergis, N.; Thursz, M.; Evans, A.; et al. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. Gastroenterology 2015, 148, 590-602.
41. Sancho-Bru, P.; Altamirano, J.; Rodrigo-Torres, D.; Coll, M.; Millan, C.; Jose Lozano, J.; Miquel, R.; Arroyo, V.; Caballería, J.; Ginès, P.; et al. Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology 2012, 55, 1931-1941.
42. Dubuquoy, L.; Louvet, A.; Lassailly, G.; Truant, S.; Boleslawski, E.; Artru, F.; Maggiotto, F.; Gantier, E.; Buob, D.; Leteurtre, E.; et al. Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut 2015, doi:10.1136/gutjnl-2014-308410.
43. Mathurin, P.; Hadengue, A.; Bataller, R.; Addolorato, G.; Burra, P.; Burt, A.; Caballeria, J.; Cortez-pinto, H.; Day, C.; Forrest, E.; et al. EASL clinical practical guidelines: Management of alcoholic liver disease. J. Hepatol. 2012, 57, 399-420.
44. O’Shea, R.S.; Dasarathy, S.; McCullough, A.J. Alcoholic liver disease. Am. J. Gastroenterol. 2010, 105, 14-32.
45. Mathurin, P.; Mendenhall, C.L.; Carithers, R.L., Jr.; Ramond, M.J.; Maddrey, W.C.; Garstide, P.; Rueff, B.; Naveau, S.; Chaput, J.C.; Poynard, T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): Individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J. Hepatol. 2002, 36, 480-487.
46. Akriviadis, E.; Botla, R.; Briggs, W.; Han, S.; Reynolds, T.; Shakil, O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial. Gastroenterology 2000, 119, 1637-1648.
47. Mathurin, P.; Louvet, A.; Duhamel, A.; Nahon, P.; Carbonell, N.; Boursier, J.; Anty, R.; Diaz, E.; Thabut, D.; Moirand, R.; et al. Prednisolone with vs. without pentoxifylline and survival of patients with severe alcoholic hepatitis: A randomized clinical trial. JAMA 2013, 310, 1033-1041.
48. Thursz, M.R.; Richardson, P.; Allison, M.; Austin, A.; Bowers, M.; Day, C.P.; Downs, N.; Gleeson, D.; MacGilchrist, A.; Grant, A.; et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N. Engl. J. Med. 2015, 372, 1619-1628.
49. Ki, S.H.; Park, O.; Zheng, M.; Morales-Ibanez, O.; Kolls, J.K.; Bataller, R.; Gao, B. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: Role of signal transducer and activator of transcription 3. Hepatology 2010, 52, 1291-1300.
50. Xing, W.W.; Zou, M.J.; Liu, S.; Xu, T.; Wang, J.X.; Xu, D.G. Interleukin-22 protects against acute alcohol-induced hepatotoxicity in mice. Biosci. Biotechnol. Biochem. 2011, 75, 1290-1294.
51. Lafdil, F.; Miller, A.M.; Ki, S.H.; Gao, B. Th17 cells and their associated cytokines in liver diseases. Cell. Mol. Immunol. 2010, 7, 250-254.
52. Mathews, S.; Gao, B. Therapeutic potential of interleukin 1 inhibitors in the treatment of alcoholic liver disease. Hepatology 2013, 57, 2078-2080.
53. Petrasek, J.; Bala, S.; Csak, T.; Lippai, D.; Kodys, K.; Menashy, V.; Barrieau, M.; Min, S.Y.; Kurt-Jones, E.A.; Szabo, G. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J. Clin Investig. 2012, 122, 3476-3489.
54. Mathurin, P.; Moreno, C.; Samuel, D.; Dumortier, J.; Salleron, J.; Durand, F.; Castel, H.; Duhamel, A.; Pageaux, G.-P.; Leroy, V.; et al. Early liver transplantation for severe alcoholic hepatitis. N. Engl. J. Med. 2011, 365, 1790-1800.